Syncona
Finance · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
8 Bloomsbury St Fl 2, London, Greater Lo...Website
www.synconaltd.comRevenue
$6.3 MillionIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
2
1
1
2
About Syncona
Syncona is a FTSE250 company dedicated to founding, building, and funding healthcare companies that aim to provide transformative treatments for patients facing significant unmet medical needs. The company manages a diversified portfolio of life science firms, including those in various clinical stages, from pre-clinical to late-stage development. Syncona's investment strategy focuses on maximizing shareholder value through key value inflection points, mergers, and liquidity events. Their commitment to sustainability ensures that they support their portfolio companies in making positive contributions to society.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Syncona your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Syncona has recently received funding, and reach out quickly before it becomes old news!
Syncona, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Syncona
Click to see if Syncona had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Syncona has new funding data
Earning: See what the market has to say on Syncona recently announced quarterly report
Product Launch: Get notified when Syncona launches new products
Check out if Syncona is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Syncona
Find more new buyers
Compare Similar Companies to Syncona
Compare insights from companies similar to Syncona, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Syncona
$6.3M
11-50
Private
-
2012
N/A
Company Profile Activity
Activity Insights
Syncona is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
Syncona is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about Syncona.
Syncona Tech Stack
A closer look at the technologies used by Syncona
Most Recent Scoops
Earnings
explained its value creation model, which consists of three core components: cost (amount invested), net asset value (NAV, reported in accounts), and risk-adjusted net present value. The company emphasized that NAV represents a historic valuation based on the most recent third-party investment.
Business Intelligence, Analytics & Insights, Accounting, Financial Reporting, Business Finance, Finance
Project
reported positive data from Spur's gene therapy for Gaucher's disease, showing significant clearance of cellular buildup in bone marrow, leading to improved blood counts and reduced pain. The company emphasized the therapy's potential to replace current enzyme replacement therapies and provide a one-time treatment option.
Product Development, Product Management, Search, Medical Research, Pharmaceuticals
Project
discussed its portfolio strategy, noting a shift towards later-stage assets due to market conditions. The company highlighted recent successes in early-stage companies like Pure Spring, which raised significant funding, and upcoming clinical entries for companies like I Amasses.
Product Development, Product Management, Corporate Strategy
Project
outlined upcoming milestones for its portfolio companies, including Beacon's phase III readout for X-linked retinitis pigmentosa and Spur's phase III trial in Gaucher's disease. The company also highlighted emerging efficacy data expected from companies like Quell and NAV young in macrophage technology.
Product Development, Product Management, Search, Medical Research, Corporate Strategy
Earnings
Accounting, Financial Reporting, Business Finance, Corporate Strategy, Finance
Syncona News & Media
Ex-Novartis CMO John Tsai joins Daiichi Sankyo | pharmaphorum
Daiichi Sankyo has named John Tsai as its new chief medical officer, replacing Ken Takeshita, who is stepping down after five years in the role.Beacon raises $75m in oversubscribed Series C | Company Announcement - Investegate
Investegate announcements from Beacon raises $75m in oversubscribed Series CPurespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseasesPurespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
Read more news
Top Finance Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Syncona
Sign Up For FreeTo access detailed company insights
Syncona is a FTSE250 company dedicated to founding, building, and funding healthcare companies that aim to provide transformative treatments for patients facing significant unmet medical needs. The company manages a diversified portfolio of life science firms, including those in various clinical stages, from pre-clinical to late-stage development.... Read More
